[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 267, "companyOfficers": [{"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "CFO, COO & Principal Accounting Officer", "fiscalYear": 2023, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 86162, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 59, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 66, "title": "Chief Technology Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy  Smith", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steve  Meyers", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Kaiser M.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay  Nayak MBBS, Ph.D.", "age": 53, "title": "Chief Strategy Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.54, "open": 8.44, "dayLow": 8.27, "dayHigh": 8.5, "regularMarketPreviousClose": 8.54, "regularMarketOpen": 8.44, "regularMarketDayLow": 8.27, "regularMarketDayHigh": 8.5, "beta": 1.256, "forwardPE": -8.242187, "volume": 873870, "regularMarketVolume": 873870, "averageVolume": 1057773, "averageVolume10days": 779490, "averageDailyVolume10Day": 779490, "bid": 6.08, "ask": 10.62, "bidSize": 200, "askSize": 200, "marketCap": 1326911360, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 11.775, "priceToSalesTrailing12Months": 21.71811, "fiftyDayAverage": 9.8162, "twoHundredDayAverage": 8.1416, "currency": "USD", "enterpriseValue": 1161941120, "profitMargins": -2.26461, "floatShares": 118912114, "sharesOutstanding": 157216992, "sharesShort": 12671361, "sharesShortPriorMonth": 16194368, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0813, "heldPercentInsiders": 0.0106, "heldPercentInstitutions": 0.91078, "shortRatio": 9.68, "shortPercentOfFloat": 0.081599995, "impliedSharesOutstanding": 157216992, "bookValue": 0.793, "priceToBook": 10.643127, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -138360992, "trailingEps": -1.29, "forwardEps": -1.02, "enterpriseToRevenue": 19.018, "enterpriseToEbitda": -10.492, "52WeekChange": 0.7546778, "SandP52WeekChange": 0.25891924, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OCUL", "underlyingSymbol": "OCUL", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "firstTradeDateEpochUtc": 1406295000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "b2e86f5b-6ae3-30af-bdc2-4b9ad5a2cf9e", "messageBoardId": "finmb_41955650", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.44, "targetHighPrice": 22.0, "targetLowPrice": 14.0, "targetMeanPrice": 18.22222, "targetMedianPrice": 18.0, "recommendationKey": "none", "numberOfAnalystOpinions": 9, "totalCash": 459689984, "totalCashPerShare": 2.948, "ebitda": -110746000, "totalDebt": 74888000, "quickRatio": 16.346, "currentRatio": 16.635, "totalRevenue": 61097000, "debtToEquity": 19.828, "revenuePerShare": 0.529, "returnOnAssets": -0.2237, "returnOnEquity": -0.72672, "freeCashflow": -55723376, "operatingCashflow": -88875000, "revenueGrowth": 0.083, "grossMargins": -0.41421002, "ebitdaMargins": -1.81263, "operatingMargins": -2.6513, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]